Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Oct;28(10):484-7.
doi: 10.1002/clc.4960281008.

Spironolactone improves diastolic function in the elderly

Affiliations
Randomized Controlled Trial

Spironolactone improves diastolic function in the elderly

Chanwit Roongsritong et al. Clin Cardiol. 2005 Oct.

Abstract

Background: Diastolic dysfunction is common in the elderly. Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age-related increases in myocardial fibrosis in old normotensive rats.

Hypothesis: Spironolactone, via its antifibrotic activity, can improve diastolic function in the elderly with isolated diastolic dysfunction.

Methods: The study was a prospective, double-blind, randomized, placebo-controlled trial. Thirty elderly subjects between 60 and 85 years of age with isolated diastolic dysfunction and no contraindications for spironolactone were randomized to 25 mg/day of spironolactone or placebo for 4 months. Mitral E/A and deceleration time, plasma levels of carboxy-terminal of procollagen type I (PICP), and brain natriuretic peptide (BNP) were measured at baseline and at the end of 4 months. Plasma level of potassium was also monitored to prevent clinically significant hyperkalemia.

Results: There was no serious adverse event or clinically significant hyperkalemia in the spironolactone group. Compared with baseline values, spironolactone significantly improved mitral E/A ratio (0.71 +/- 0.08 vs. 0.84 +/- 0.19, p = 0.025) and deceleration time (285.5 +/- 73.1 vs. 230.0 +/- 54.7, p = 0.035). There were no significant differences in the magnitude of change in the levels of PICP and BNP between the two treatment groups.

Conclusion: Spironolactone may improve diastolic function in the elderly.

PubMed Disclaimer

References

    1. Kannel WB, Belanger AJ: Epidemiology of heart failure: Am Heart J 1991; 121: 951–957 - PubMed
    1. Kannel WB: Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987; 8 (suppl F): 23–26 - PubMed
    1. Kitzman DW: Diastolic function in the elderly, genesis and diagnostic and therapeutic implications. Cardiol Clin 2000; 18: 597–617 - PubMed
    1. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure, interfering the aldosterone‐cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227–1232 - PubMed
    1. Brilla C, Weber K: Reactive and reparative myocardial fibrosis in arterial hypertension in rats. Cardiovasc Res 1992; 26: 671–677 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources